ArticlePostepy dermatologii i alergologii2017
Safety and efficacy of venom immunotherapy: a real life study.
Article in Postepy dermatologii i alergologii, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- MicroRNAs-Are They Possible Markers of Allergic Diseases and Efficient Immunotherapy?International journal of molecular sciences · 2026Review
- Diagnostics and monitoring in Hymenoptera venom allergy: current and future perspectives.Frontiers in allergy · 2026Review
- Comparison of basophil activation testing and component-resolved diagnosis in patients with cross-reactive intradermal results after anaphylactic reactions to hymenoptera venom.Scientific reports · 2025Article
- Patients with detectable KIT p.D816V in peripheral blood are at high risk for adverse systemic events during venom immunotherapy and treatment failure.Clinical and translational allergy · 2025Article
- Therapeutic Potential and Mechanisms of Bee Venom Therapy: A Comprehensive Review of Apitoxin Applications and Safety Enhancement Strategies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Venom Immunotherapy Does Not Affect Survival of Patients with Malignant Tumor in Poland.Journal of clinical medicine · 2024Article
- Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies.Journal of nanobiotechnology · 2023Review
- Immunologic, genetic, and ecological interplay of factors involved in allergic diseases.Frontiers in allergy · 2023Review
- Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS).Orphanet journal of rare diseases · 2022Article
- Review
- Bioactive Peptides and Proteins from Wasp Venoms.Biomolecules · 2022Review
- Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans.Frontiers in allergy · 2022Article
- A Review of Honeybee Venom Allergens and Allergenicity.International journal of molecular sciences · 2021Review
- Wasp Venom Biochemical Components and Their Potential in Biological Applications and Nanotechnological Interventions.Toxins · 2021Review
- Article
- From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery.Frontiers in pharmacology · 2020Review
- Venom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit.Postepy dermatologii i alergologii · 2019Article
- Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.Human vaccines & immunotherapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVenom immunotherapy (VIT) is recommended as the first-line treatment for patients allergic to Hymenoptera venom.
aimTo analyze the safety and efficacy of VIT in a real life setting. MATERIAL AND
methodsOne hundred and eighty patients undergoing VIT were studied to evaluate the safety, efficacy, incidence and nature of symptoms after field stings and adverse reactions to VIT.
resultsSignificantly more patients were allergic to wasp than bee venom (146 vs. 34,
conclusionsVenom immunotherapy is highly efficacious and safe as most of the adverse events during the induction and maintenance phase are mild and local. Side effects of VIT are more common in subjects on bee VIT. Beekeeping and female sex are associated with a higher risk of allergy to Hymenoptera venom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.